---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Definition and etiology"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Definition and etiology. Topics: Definition: FDA draft guidance on trials in treatment-resistant depression, Definition: EMA guideline on treatment resistance, Definition: regulatory definition and absence of a validated consensus definition, Definition: review of expert and trial definitions for AHRQ and CMS, and 12 further topics. 16 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: FDA draft guidance on trials in treatment-resistant depression

> “Response, partial response, and nonresponse exist on a continuum with no universally accepted”
> “efficacy in adjunctive therapy versus treatment-resistant depression (TRD) are quite different.”
> “Patients who have not responded to more than one prior”
> “antidepressant, administered at an adequate dose and duration, should be enrolled in TRD”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-2.2.1.1-2"></a>

### Definition: EMA guideline on treatment resistance

> “Treatment resistance in depression develops in a continuum with progressively higher resistance depending on the number and nature of interventions failed.”
> “Typically, TRD trials recruit patients with demonstrated history of failure of at least two antidepressants deriving from the group(s) of products commonly used as first line treatment (of the same or a different class) prescribed at an adequate dosage for an adequate duration, with adequate affirmation of treatment adherence.”
> “However, the inclusion of patients with one failed treatment at a maximum tolerated dose and for an adequate duration can also be considered.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.1.1-3"></a>

### Definition: regulatory definition and absence of a validated consensus definition

> “A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently exist.”
> “The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment).”
> “The EMA definition, contrary to the FDA one, explicitly states that the failed antidepressants can be from the same or different mechanistic classes.”
> “Limitations of the FDA and EMA definitions are that they do not explicitly operationalize non‐response, and do not consider psychotherapeutic interventions, regarded as first‐line treatments for mild or moderate depression by most guidelines”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.1-4"></a>

### Definition: review of expert and trial definitions for AHRQ and CMS

> “We found that no consensus definition existed for TRD. The most common TRD definition for major depressive disorder required a minimum of two prior treatment failures and confirmation of prior adequate dose and duration.”
> “Our systematic review found that only 17% of intervention studies enrolled samples meeting the most frequently specified criteria for TRD.”

Source: [Gaynes et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31638723/)

<a id="topic-2.2.1.1-5"></a>

### Definition: systematic review of definitions in research and clinical practice

> “In total, 155 definitions for TRD were identified in the published literature, and 48.4% of all definitions specified requirement of at least 2 treatment failures.”
> “Key informant interviews indicated the concept of TRD is rarely employed in clinical practice.”

Source: [Brown et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6591751/)

<a id="topic-2.2.1.1-6"></a>

### Definition: Delphi consensus criteria for regulatory clinical trials

> “Based on a number of guidelines and other expert documents [22–25], in this report we adopt the definition of TRD as indicating individuals who show a reduction of less than 25% in MDD severity to at least two antidepressants, and of PRD as indicating individuals who show a reduction of between 25% and <50% in MDD severity to at least one antidepressant.”
> “We recommend (with moderate consensus, 74%) that the criteria of ‘adequate dose and duration’ is the minimal effective dosage, that is, the minimal approved dosage, administered for at least four weeks.”

Source: [Sforzini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/)

<a id="topic-2.2.1.1-7"></a>

### Definition: CANMAT 2023 guideline

> “There is no universal consensus on a definition for TRD, but the one most frequently used is failure to respond to 2 or more antidepressant trials at a therapeutic dose and adequate duration.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.1.1-8"></a>

### Definition: population in the ICER assessment of psilocybin

> “but a common definition is inadequate response to two different antidepressant medications despite an adequate dose and duration of treatment.”
> “adults ages 18 years and older with major depressive disorder, without psychotic features, and for whom two or more prior antidepressants prescribed at adequate dose and duration, during the current episode, have not resulted in adequate therapeutic benefit.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.1.1-9"></a>

### Related concept: difficult-to-treat depression

> “The group proposed that DTD be defined as "depression that continues to cause significant burden despite usual treatment efforts".”
> “While DTD would seem to have clinical utility, its specificity and objectivity may be insufficient to define clinical populations for regulatory trial purposes”

Source: [McAllister-Williams et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32217227/)

> “DTD is a term proposed to extend the TRD concept and to better characterize the collaborative journey of patients and their clinicians when standard treatments have not been effective.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.1.1-10"></a>

### Etiology: heterogeneous causal mechanisms

> “Treatment Resistant Depression (TRD) represents a heterogeneous state with likely multiple causal mechanisms.”
> “The extent to which individuals with TRD versus treatment-responsive MDD differ in etiology or pathophysiology remains mostly obscure”
> “Both childhood adversity and stress in adulthood predict increased TRD following antidepressant treatments”

Source: [Akil et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729118/)

<a id="topic-2.2.1.1-11"></a>

### Risk factors: familial aggregation in a nationwide Taiwanese cohort

> “TRD was defined as having experienced at least 3 distinct antidepressant treatments in the current episode, each with adequate dose and duration, based on the prescribing records.”
> “First-degree relatives of individuals with TRD had lower incomes, more physical comorbidities, higher suicide mortality, and increased risk of developing TRD (aRR, 9.16; 95% CI, 7.21-11.63) and higher risk of other psychiatric disorders than matched control individuals, including schizophrenia (aRR, 2.36; 95% CI, 2.10-2.65), bipolar disorder (aRR, 3.74; 95% CI, 3.39-4.13), major depressive disorder (aRR, 3.65; 95% CI, 3.44-3.87), attention-deficit/hyperactivity disorders (aRR, 2.38; 95% CI, 2.20-2.58), autism spectrum disorder (aRR, 2.26; 95% CI, 1.86-2.74), anxiety disorder (aRR, 2.71; 95% CI, 2.59-2.84), and obsessive-compulsive disorder (aRR, 3.14; 95% CI, 2.70-3.66).”

Source: [Cheng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10993159/)

<a id="topic-2.2.1.1-12"></a>

### Risk factors: heritability and polygenic associations in UK primary care cohorts

> “In UKB, TRD vs healthy controls and non-TRD vs healthy controls h2SNP was comparable (0.25 [SE = 0.04] and 0.19 [SE = 0.02], respectively).”
> “TRD vs non-TRD was positively associated with the PRS of attention deficit hyperactivity disorder, with lower socio-economic status, obesity, higher neuroticism and other unfavourable clinical characteristics.”

Source: [Fabbri et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8505242/)

<a id="topic-2.2.1.1-13"></a>

### Risk factors: baseline predictors in US commercial claims

> “TRD patients at baseline were younger; 10.87% were between 18 and 19 years old versus 7.64% in the no‐TRD group, risk ratio (RR) = 1.42 (95% confidence interval [CI] 1.37–1.48).”
> “At 3.68, fatigue had the highest RR (95% CI 3.18–4.25). TRD patients had substance use disorders, psychiatric conditions, insomnia, and pain more often at baseline than non‐TRD patients.”

Source: [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/)

<a id="topic-2.2.1.1-14"></a>

### Risk factors: sociodemographic characteristics

> “It is established that older persons more frequently fail multiple monoamine‐based antidepressant treatments, which may be taken as evidence that TRD is more common in this subpopulation”
> “It is not established whether female sex is a risk factor for TRD”
> “Socioeconomic position is a risk factor for TRD in persons receiving monoamine‐based antidepressants. For example, in the STAR*D trial, persons meeting level 2 criteria (i.e., inadequate response to two sequential antidepressant regimens) were more likely to report lower income and dependence on the public health system”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.1-15"></a>

### Risk factors: childhood maltreatment and life stress

> “There are also studies providing evidence that a reported history of childhood emotional abuse is associated with recurrent depression, persistent depression, as well as treatment resistance to antidepressants”
> “The international Study to Predict Optimized Treatment for Depression (iSPOT‐D) reported that, amongst adults with MDD and a history of trauma between the ages of 4 and 7 years, only 15.9% achieved remission after 8 weeks of treatment with escitalopram, sertraline or venlafaxine, compared to 84.1% in individuals with no history of childhood trauma”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.1-16"></a>

### Risk factors: illness severity, episode duration, and clinical features

> “Greater baseline severity is a highly replicated risk factor for TRD, and is indeed included in some frameworks as a variable in the hierarchical characterization of the condition.”
> “Illness duration is also highly associated with TRD, with replicated evidence indicating that the length of a depressive episode is inversely proportional to the probability of treatment response”
> “Psychotic symptoms affect approximately 20% of adults with MDD and are highly associated with TRD”
> “Results from the STAR*D trial indicate that persons presenting with anxious depression exhibit attenuated antidepressant response and are more likely to develop TRD”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

Additional sources: [Conway et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27784055/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
